Investigation of Nosocomial Urinary Tract Infections Post Transplantation, Main Pathogens, and Sensitivity Tests

IF 0.3 Q4 PHARMACOLOGY & PHARMACY Current Drug Therapy Pub Date : 2023-11-28 DOI:10.2174/0115748855271275231115064229
Z. Ghamari
{"title":"Investigation of Nosocomial Urinary Tract Infections Post Transplantation, Main Pathogens, and Sensitivity Tests","authors":"Z. Ghamari","doi":"10.2174/0115748855271275231115064229","DOIUrl":null,"url":null,"abstract":"Regarding end-stage organ disease, transplantation is recommended as the best therapeutic management. After organ transplantation, the incidence of nosocomial urinary tract infections (NUTIs) due to multidrug-resistant Gram-negative bacilli increases. Regarding end-stage organ disease organ transplantation recommended as the best therapeutic management. After organ transplantation the incidence of urinary tract infections (UTIs) due to multidrug-resistant Gram-negative bacilli is increasing The study aimed to investigate NUTIs post-transplantation, the main pathogens involved, and sensitivity tests conducted in a tertiary hospital in Isfahan, Iran. A retrospective survey on patients admitted to a tertiary hospital in Isfahan (Alzahra), Iran, was performed between 27 March, 2017, and 9 February, 2022. The information recorded included the date of infection, date of hospitalization, gender, age, type of pathogens, and resistance or sensitivity to antibiotics. 73 kidney transplant recipients (61% females) with a mean age of 43. 2 ± 15.1 years were included. Within this population involving both genders, the main pathogens involved in NUTIs were as follows: Escherichia coli (30%), Klebsiella pneumonia (19%), Candida albicans and non-albicans (14%), Enterococcus faecalis (12%), Enterobacteriaceae (8%), Pseudomonas aeruginosa (6%), Staphylococcus spp. (6%), Acinetobacter baumannii (4%), and Streptococcus spp. (4%). Antibiotic susceptibility testing showed the most sensitivity of isolates against amikacin (n=29; 66%), meropenem (n= 28; 64%), piperacillin/tazobactam (n=26; 54%), cefepime (n= 25; 40%), ceftazidime (n= 27; 30%), ciprofloxacin (n= 40; 18%), and co-trimoxazole (n= 29; 10%). 72 kidney transplant recipients (61 Escherichia coli, Klebsiella pneumonia, and Candida spp. are the major causes of NUTIs within organ-transplanted recipients. Amikacin, meropenem, and piperacillin/tazobactam have shown more than 50% sensitivity against isolates. Further evidence-based management associated with the different spectrum antibiotics and overall antimicrobial success rate is recommended to be advantageous.","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748855271275231115064229","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Regarding end-stage organ disease, transplantation is recommended as the best therapeutic management. After organ transplantation, the incidence of nosocomial urinary tract infections (NUTIs) due to multidrug-resistant Gram-negative bacilli increases. Regarding end-stage organ disease organ transplantation recommended as the best therapeutic management. After organ transplantation the incidence of urinary tract infections (UTIs) due to multidrug-resistant Gram-negative bacilli is increasing The study aimed to investigate NUTIs post-transplantation, the main pathogens involved, and sensitivity tests conducted in a tertiary hospital in Isfahan, Iran. A retrospective survey on patients admitted to a tertiary hospital in Isfahan (Alzahra), Iran, was performed between 27 March, 2017, and 9 February, 2022. The information recorded included the date of infection, date of hospitalization, gender, age, type of pathogens, and resistance or sensitivity to antibiotics. 73 kidney transplant recipients (61% females) with a mean age of 43. 2 ± 15.1 years were included. Within this population involving both genders, the main pathogens involved in NUTIs were as follows: Escherichia coli (30%), Klebsiella pneumonia (19%), Candida albicans and non-albicans (14%), Enterococcus faecalis (12%), Enterobacteriaceae (8%), Pseudomonas aeruginosa (6%), Staphylococcus spp. (6%), Acinetobacter baumannii (4%), and Streptococcus spp. (4%). Antibiotic susceptibility testing showed the most sensitivity of isolates against amikacin (n=29; 66%), meropenem (n= 28; 64%), piperacillin/tazobactam (n=26; 54%), cefepime (n= 25; 40%), ceftazidime (n= 27; 30%), ciprofloxacin (n= 40; 18%), and co-trimoxazole (n= 29; 10%). 72 kidney transplant recipients (61 Escherichia coli, Klebsiella pneumonia, and Candida spp. are the major causes of NUTIs within organ-transplanted recipients. Amikacin, meropenem, and piperacillin/tazobactam have shown more than 50% sensitivity against isolates. Further evidence-based management associated with the different spectrum antibiotics and overall antimicrobial success rate is recommended to be advantageous.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
器官移植后尿路感染调查、主要病原体和敏感性测试
对于终末期器官疾病,移植被推荐为最佳治疗方法。器官移植后,耐多药革兰氏阴性杆菌引起的院内尿路感染(NUTIs)发病率增加。 对于终末期器官疾病,建议将器官移植作为最佳治疗方法。这项研究旨在调查器官移植后的尿路感染、主要病原体以及在伊朗伊斯法罕一家三级医院进行的药敏试验。 研究于 2017 年 3 月 27 日至 2022 年 2 月 9 日期间对伊朗伊斯法罕(Alzahra)一家三级医院的住院患者进行了回顾性调查。所记录的信息包括感染日期、住院日期、性别、年龄、病原体类型以及对抗生素的耐药性或敏感性。 研究对象包括 73 名肾移植受者(61% 为女性),平均年龄为 43.2 ± 15.1 岁。在这一涉及男女的人群中,NUTIs 所涉及的主要病原体如下:大肠埃希菌(30%)、肺炎克雷伯菌(19%)、白色念珠菌和非白色念珠菌(14%)、粪肠球菌(12%)、肠杆菌科(8%)、铜绿假单胞菌(6%)、葡萄球菌属(6%)、鲍曼不动杆菌(4%)和链球菌属(4%)。抗生素药敏试验显示,分离菌株对阿米卡星(n=29;66%)、美罗培南(n=28;64%)、哌拉西林/他唑巴坦(n=26;54%)、头孢吡肟(n=25;40%)、头孢他啶(n=27;30%)、环丙沙星(n=40;18%)和联合曲唑(n=29;10%)最敏感。 72 名肾移植受者(61 例)大肠埃希菌、克雷伯氏肺炎和念珠菌属是器官移植受者发生 NUTI 的主要原因。阿米卡星、美罗培南和哌拉西林/他唑巴坦对分离菌株的敏感性超过 50%。建议对不同谱系的抗生素和总体抗菌成功率进行进一步的循证管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Drug Therapy
Current Drug Therapy PHARMACOLOGY & PHARMACY-
CiteScore
1.30
自引率
0.00%
发文量
50
期刊介绍: Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.
期刊最新文献
Revolutionizing Healthcare and Drug Discovery: The Impact of Artificial Intelligence on Pharmaceutical Development Advancements in Natural Alkaloid-Loaded Drug Delivery Systems for Enhanced Peptic Ulcer Treatment: A Review Internet of Healthcare Things Based Detection of EEG Epileptic Seizures: A Smart System Exploring the Potential of Pectin for Gastro Retentive Drug Delivery Systems: From Orchard to Drug Delivery Gold Nanoparticles: An Emerging Novel Technology for Targeted Delivery System for Site-Specific Diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1